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Microscopic polyangiitis (MPA) is a systemic necrotizing vasculitis that affects small vessels with no
immune deposits. MPA is a rare disease. The incidence of MPA is approximately 1:100.000 per year. The
etiology of this disease is unknown. Pulmonary involvement is mainly characterized with ground-glass
attenuation, consolidation, thickening of bronchovascular bundles, and honeycombing on computerized
tomography (CT). We report a patient with an atypical pattern of pulmonary involvement which is
diffuse peribronchovascular nodular inﬁltration. A 59-year-old male patient presented with symptoms of
shortness of breath, cough, purulent sputum, back pain and hemoptysis. Laboratory studies depicted
increased serum creatinine levels, hematuria and proteinuria. His chest X-ray and CT of thorax showed
bilateral diffuse peribronchovascular nodular inﬁltrations. Circulating myeloperoxidase (MPO) anti-
neutrophil cytoplasmic antibody (p-ANCA) was positive. Renal biopsy was obtained because of hema-
turia, proteinuria and increased creatinine level and revealed crescentic glomerulonephritis associated
with small vesel vasculitis which was consistent with MPA. He was treated with corticosteroid and
cyclophosphamide. At the end of two months of treatment, renal function and other pulmonary
symptoms improved.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Microscopic polyangiitis (MPA) is one of the systemic necro-
tizing vasculitides that is included in the pulmonary renal
syndromes.1–4 MPA is characterized histologically by the involve-
ment of small vessels and the absence of granuloma.3,5 MPA was
initially recognized as a particular type of polyarteritis nodosa
(PAN) with, in most cases, rapidly progressive necrotizing glomer-
ulonephritis (RPGN), crescentic glomerulonephritis and sometimes
with lung haemorrhage. MPA affects men more than women. Anti-
neutrophil cytoplasmic antibodies (ANCA) are positive in MPA
patients. Pulmonary involvement is seen in 22% of the patients and
mainly characterized with ground-glass attenuation, consolidation,
thickening of bronchovascular bundles, and honeycombing on
computerized tomography (CT).6–8 We report a patient with aniﬁcant ﬁnancial involvement
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rved.atypical pattern of pulmonary involvement seen on CT scans which
is diffuse peribronchovascular nodular inﬁltration.2. Case report
A 59-years old male patient was admitted to our hospital with
complaints of shortness of breath, cough with purulent sputum,
back pain, arthralgia and hemoptysis for 15 days. His past medical
history was unremarkable. He was a retired building construction
worker. He was an ex-smoker with a past smoking history of
30 pack-year. Physical examination including dermatologic
examination was unremarkable except for ﬁne crackles heard on
the lung bases. Pathological laboratory ﬁndings were as follow;
hemoglobin: 10.9 g/dl, Na: 132 mEq/lt, blood urea nitrogen: 23 mg/
dl, creatinine: 1.3 mg/dl, albumin: 3.0 g/dl, erythrocyte sedimen-
tation rate:75 mm/h. There was no eosinophilia in peripheral blood
smear. Pulmonary function test were as below; Forced Vital
Capacity (FVC): 78% of predicted (2.83 lt), Forced Expiratory
Volume in one second (FEV1): 43% of predicted (1.24 lt), FEV1/FVC:
44%. Arterial blood gas analysis while breathing room air was PaO2:
68.9 mmHg, PaCO2:36 mmHg, pH:7.40, SO2:97.3%. Posteroanterior
chest X-ray revealed bilateral pulmonary inﬁltrations (Fig. 1). CT
of thorax demonstrated bilateral peribronchovascular nodular
Fig. 1. PA chest X-ray of patient with bilateral pulmonary inﬁltrations.
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(Fig. 2(a)). Three sputum samples were negative for acid-fast bacilli.
Tuberculosis skin test was negative. Fiberoptic bronchoscopy
revealed edematous mucosa and hemorage coming from both
bronchial systems. The bronchoalveolar lavage (BAL) return was
also increasingly bloody. Perl’s Prussian blue staining revealed
elevated percentage (28%) of hemosiderin-laden macropahges in
BAL. There was no extraordinary ﬁndings in ﬂuid cytology
and cultures. During follow up, blood urea nitrogen (BUN) and
serum creatinine levels increased progressively in 5 days. In spot
urinanalysis, there was proteinurea. Creatinine clearance was
23.85 ml/min. Renal ultrasound revealed bilaterally grade I paren-
chymal echogenity. Transcutaneous renal biopsy was applied
which revealed diffuse cresentic glomerulonephritis associated
with small vessel vasculitis. There was no evidence of granuloma-
tous inﬂamation and eosinophilic inﬁltration. While anti-
glomerular basement membrane antibody was negative, p-ANCA
speciﬁc to myeloperoxidase (MPO) was positive. Based on these
ﬁndings, microscopic polyangiitis (MPA) was diagnosed. We
applied combined immunosuppressive treatment for remission
induction with methylprednisolon 1 mg/kg/day (tapered weekly)
and pulse cyclophosphamide 1 gr/month for 2 months. ThenFig. 2. CT of thorax revealed; (a)bilateral peribronchovascular nodular inﬁltmaintenance therapy was started with methylprednisolon 10 mg/
day and azathioprine at 2 mg/kg/day for 12 months. At the end of
two months of therapy, blood urea nitrogen and serum creatinine
level decreased progressively. Renal function and pulmonary
symptoms signiﬁcantly improved along with the lesions seen on CT
of thorax (Fig. 2(b)). Now we follow up this patient for 3 years in
complete remission.3. Discussion
MPA is one of the vasculitides that is included in the pulmonary
renal syndromes. The incidence of MPA is approximately 1:100.000
per year. Males are more commonly affected than females.3 RPGN is
one of its major characteristics. Other clinical symptoms such as
alveolar haemorrhage, cutaneous, musculoskeletal, gastrointestinal
system, neurological and ear-nose-throat involvement may also be
found but occur less frequently.1
MPA, unlike PAN, cannot always be considered to be acute
disease. Lauque et al. showed that the median time between onset
of symptom and diagnosis of MPA was highly variable between
2 weeks and 10 years.6 In the present case, the duration of symp-
toms was about two weeks. Savage et al. observed that extra-renal
symptoms such as arthralgia or hemoptysis might occur several
months or years before the acute phase of the disease.5,7 Our
patient was admitted to our hospital with the symptom of
hemoptysis, back pain and arthralgia.
Alveolar hemorrhage (AH) was reported in 12–79% of the
patients with MPA.6 Subclinic cases of alveolar hemorrhage can
occur.3,5 AH is an important contributory factor to both morbidity
and mortality in MPA.3,6 Our patient was admitted with the
symptom of hemoptysis. Bronchoscopical and radiological ﬁndings
(graund glass opacities) were associated with AH.
Patients with MPA have similar chest imaging features
with those with AH due to Goodpasture syndrome, Wegener
granulomatosis, or lupus. Interstitial and airspace ﬁbrosis are
frequent ﬁndings in patients with immune AH. Some pulmonary
interstitial ﬁbrosis cases inMPAwere presented in literature.1 Chest
radiographic features seen in MPA consist of patchy, bilateral
airspace opacities caused by AH. Most of the opacities are located
in both the upper and lower lung ﬁelds. Also rarely, normal chest
X-ray can be seen in MPA patients.6 Both Lee et al.9 and Lohrmann
et al.10 reported thoracic manifestation ofWegener granulomatosis.
Most common pattern was reported as nodules or masses
(90%). 41% of these nodules were seen peribronchovascular in
distrubition.9 Also bronchial wall thickening was reported by Lee etration, (b) improvement of inﬁltration after two months of treatment.
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reviewed the CT ﬁndings in 51 MPA patients with pulmonary
involvement. The CT ﬁndings consisted of ground-glass attenuation
in 94% of patients, consolidation in 78%, thickening of broncho-
vascular bundles in 51%, honeycombing in 37%, nodules larger than
1 cm in 29%, bronchiectasis in 27%, pleural effusion in 27% and
enlarged mediastinal lymph nodes in 18%. The predominant zonal
distribution was the lower zone in 39%, the upper zone in 22%, and
a random distribution in 39%.8 Okada et al.11 also reported that
ill-deﬁned centrilobular nodules of ground-glass attenuation were
seen 27 of 48MPA patients (56%). In English literature, we could not
ﬁnd any study or case about peribronchovascular nodular inﬁltra-
tion in MPA. In present case, CT of thorax showed ground-glass
attenuations and bilateral diffuse peribronchovascular nodular
inﬁltration, which was an uncommon CT ﬁnding for MPA.
ANCA antibodies are useful diagnostic markers for MPA.
Circulating ANCA antibodies are present in 74.5% of patients
with MPA. The p-ANCA pattern with antibodies to MPO is most
closely associated with MPA. Lauque et al. revealed that p-ANCA
antibodies were present in 93% of MPA patient. Presence of c-
ANCA was reported in only 8 to 10% of the patients in the
literature.5,6 In this case, p-ANCA with anti-MPO activity was
positive. Also, antiglomerular basement membrane antibody was
negative, which was closely associated with Goodpasture’s
syndrome.
Lung biopsy is not usually advised in the setting of immune AH
when speciﬁc diagnosis can be established reliably by other easier
tissue biopsies and by serum assays for ANCA or antiglomerular
basement membrane antibody.3,6,12,13 Renal biopsy was a valuable
tool that yielded a rapid diagnosis of crescentic glomerulonephritis
and allowed a rapid start of treatment, even in patients with
microscopic hematuria without renal failure.6 In our case, renal
biopsy revealed cresentic glomerulonephritis without granuloma-
tous inﬂammation and immune deposits. Additionally, clinical
ﬁndings and presence of p-ANCA, we concluded that our case were
MPA with pulmonary and renal involvement.
The severity of pulmonary and renal involvement often requires
intensive treatment with high doses of corticosteroids and pulse
cyclophosphamide and if needed hemodialysis. Renal function may
improve markedly with early treatment in most patient even in
those with initial severe renal failure.14–16 Relapses are frequent in
MPA, occuring in 25–54% of patient who survive the ﬁrst months.
Median time to relapses was reported as 22 months.6,16,17 We
applied immunosuppressive treatment of 2 months for induction
and 12 months for maintenance. There was no need for performing
hemodialysis. Renal functions improved and recovery was seen in
CT of thorax and symptomatology of patient after induction. Wefollowed up the patient for about 3 years and no relapse had been
occured till now.
We presented a case of MPA with unusual pulmonary manifes-
tation of diffuse peribronchovascular nodular inﬁltration, treated
with corticosteroid and cyclophosphamide with no need to dialysis
and got improvement of clinical and radiological without relapse
of three years follow.
Conﬂict of interest
I declare on behalf of my co-authors and myself that we do not
have any conﬂict of interest to declare.
References
1. Eschun GM, Mink SN, Sharma S. Pulmonary interstitial ﬁbrosis as a presenting
manifestation in perinuclear antineutrophilic cytoplasmic antibody micro-
scopic polyangiitis. Chest 2003;123:297–301.
2. Lhote F, Cohen P, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis, and
Churg-Strauss syndrome. Lupus 1998;7:238–58.
3. Collins EC, Quismorio FP. Pulmonary involvement in microscopic polyangiitis.
Curr Opin Pulm Med 2005;11:447–51.
4. Gu¨lbay BE, Celik G, Kumbasar O, et al. Microscopic polyangiitis with unusual
lung involvement. Respirology 2005;10:678–81.
5. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical
and laboratory ﬁndings in eighty-ﬁve patients. Arthritis Rheum 1999;42:421–30.
6. Lauque D, Cadranel J, Lazor R, et al. Microscopic polyangiitis with alveolar
hemorrhage: a study of 29 cases and review of the literature. Medicine (Balti-
more) 2000;79:222–33.
7. Savage C, Winearls C, Evans D. Microscopic polyarteritis:presentation,
pathology and prognosis. Q J Med 1985;56:467–83.
8. Ando Y, Okada F, Matsumoto S, et al. Thoracic menifestation of myeloperox-
idase-antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease:
CT ﬁndings in 51 patients. J Comput Assist Tomogr 2004;28. p. 710–6.
9. Lee KS, Kim TS, Fujimoto K, Moriya H, Watanabe H, Tateishi U, et al. Thoracic
manifestation of Wegener’s granulomatosis: CT ﬁndings in 30 patients.
Eur Radiol 2003;13:43–51.
10. Lohrmann C, Uhl M, Kotter E, Burger D, Ghanem N, Langer M. Pulmonary
manifestations of wegener granulomatosis: CT ﬁndings in 57 patients and
a review of the literature. Eur J Radiol 2005;53:471–7.
11. Okada F, Ando Y, Yoshitake S, Ono A, Tanoue S, Matsumoto S, et al. Clinical/
pathologic correlations in 553 patients with primary centrilobular ﬁndings on
high-resolution CT scan of the thorax. Chest 2007;132(6):1939–48.
12. Burns A. Pulmonary vasculitis. Thorax 1998;53:220–7.
13. Cordier JF. A lung biopsy is unnecessary in the management of ANCA positive
patients with chest-roentgenographic abnormalities. Sarcoidosis Vasc Diffuse
Lung Dis 1996;13:235–7.
14. Zandman-Goddard G. Diffuse alveolar hemorrhage in autoimmune diseases.
IMAJ 2002;4:461–2.
15. Austin JH, Muller NL, Friedman PJ, et al. Glossary of terms for computed
tomography of the lungs: recommendations of the nomenclature committee of
the Fleischner society. Radiology 1996;200:327–31.
16. Nachman PH, Hogan SL, Jennette JC, et al. Treatment response and relapse in
antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis
and glomerulonephritis. J Am Soc Nephrol 1996;7:33–9.
17. Donaghi M, Rees A. Cigarette smoking and lung hemorrhage in glomerulone-
phritis caused by autoantibodies to glomerular basement membrane. Lancet
1983;2:1390–3.
